aadibio.com - WHWK Operating profit EBITDA
Aadi Bioscience Inc (WHWK) leads in precision oncology therapy, developing breakthrough methods to combat rare tumors. Operating income before taxes and depreciation demonstrates financial efficiency, with the indicator standing at 0.00. Market capitalization is based on the commercialization of the drug Fyarro through insurance funds. Business stability is ensured by the humanitarian status of the medicine and the absence of geopolitical risks in the US.
Aadi Bioscience (WHWK) - metric breakdowns and financial figures
- current quotes and average value forecast:
- issuer market value details:
- book value of equity indicators:
- debt level and financial liquidity data:
Total Debt to Capital Aadi Bioscience Inc|WHWK - Long-Term Debt to Capital|Short-Term Debt to Capital Aadi Bioscience, Inc.|WHWK - Company Aggregate Debts|Debt to Book Value Ratio Aadi Bioscience|WHWK - Company Long-Term Debts|Short-Term Debt Volume Aadi Bioscience|Intermediate Coverage Ratio aadibio.com
- earnings and market ratios statistics:
WHWK - Net Profit|Expected Profit Aadi Bioscience Inc|WHWK - P/E Multiple|Market Cap to Projected Earnings Aadi Bioscience, Inc.|WHWK - Price/Earnings to Growth Ratio|Company Value to EBITDA Aadi Bioscience|WHWK - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Aadi Bioscience|WHWK - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months aadibio.com|WHWK - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Aadi Bioscience Inc
Summary company analytics:Aadi Bioscience Inc - WHWK
For Aadi Bioscience Inc (WHWK), the commercial implementation of Fyarro and the development of mTOR inhibitor-based therapies directly determine the volume of incoming cash flows. By analyzing operating profit dynamics, investors can see actual sales proceeds before non-cash charges, allowing for a real-time assessment of cash flow disruptions and the ability to distinguish random fluctuations from a systemic business sustainability crisis.
Who Aadi Bioscience Inc competes with
ONC - Operating profit before deduction of amortization|HALO: Operating profit before deduction of amortization|RVMD - Operating profit EBITDA|Ascentage Pharma (AAPG) - Profit before payment of interest, taxes and amortization|CG Oncology Inc - Income before deduction of interest, taxes and amortization|URGN (UroGen) - Operating profit EBITDA|Profit before interest, taxes and amortization Bicara Corp BCAX|Operating profit EBITDA PSNL|Operating profit EBITDA erasca.com (ERAS)|Operating profit EBITDA DCTH (Delcath Systems)|Operating profit EBITDA Y-mAbs Therapeutics Inc YMAB|Aura Bio - Operating profit EBITDA|CADL (Candel Therapeutics) - Operating profit before amortization|ARAY: Operating profit EBITDA|SLS - Operating income before deduction of amortization|Operating profit before deduction of amortization ACTU|CTOR: Income before deduction of interest, taxes and amortization|Operating profit EBITDA HURA|Profit before payment of interest, taxes and amortization TARA (Protara Tx)|Operating profit EBITDA FATE (Fate Therapeutics, Inc.)|Operating income before deduction of amortization TScan Therapeutics Inc (TCRX)|CSBR - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization XBiotech Inc.|cel-sci.com (CVM) - Profit before payment of interest, taxes and amortization|OSTX - Operating income before deduction of amortization|RADX (Radiopharm Theranostics) - Operating profit EBITDA|Operating profit before deduction of amortization Artiva (ARTV)|Operating profit EBITDA ANL|Operating income before deduction of amortization Veru Inc|Operating profit EBITDA TPST (Tempest Tx)|Xilio Therapeutics Inc (XLO) - Profit before interest, taxes and amortization|RENB - Profit before payment of interest, taxes and amortization|MURA (Mural Oncology plc) - Operating profit before amortization|KAPA: Operating profit EBITDA|Operating profit before deduction of amortization OnKure Therapeutics|GDTC (CytoMed Therapeutics Ltd) - Operating profit EBITDA|Profit before interest, taxes and amortization Curis Corp CRIS|Operating profit before deduction of amortization APLM (Apollomics, Inc.)|THAR (tharimmune.com) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA ADVB (Advanced Biomed)|Operating income before deduction of amortization Genprex Inc. (GNPX)|CLDI - Profit before payment of interest, taxes and amortization|SBFM (sunshinebiopharma.com) - Operating profit before amortization|XBIO: Operating profit EBITDA|Operating profit before deduction of amortization salariuspharma.com|Operating profit before deduction of amortization PPBT|Operating profit before deduction of amortization AON (AONC)|Operating profit EBITDA BGNE|CKPT (Checkpoint Therapeutics Inc) - Income before deduction of interest, taxes and amortization|Elevation Oncology - Operating profit before deduction of amortization|ICAD - Operating profit before deduction of amortization|IKNA - Profit before payment of interest, taxes and amortization|NTBL - Operating profit EBITDA|VIRX: Operating profit EBITDA|Operating profit before deduction of amortization MorphoSys Corporation|NAYA (NAYA Biosciences) - Operating profit EBITDA|Operating profit EBITDA ascentage.com
